Neurosense Therapeutics Ltd.

As of May 29, 2025, the technical trend is bullish with moderate strength, supported by a bullish MACD, moving averages, and Bollinger Bands, although the weekly RSI shows some short-term weakness.

Neurosense Therapeutics Ltd. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $2 million and a market cap of $57.57 million. Key financial metrics include a P/E ratio of NA, a dividend yield of 0.00%, and a return on equity of -319.32%.

As of Jun 18, Neurosense Therapeutics Ltd. has a market capitalization of 57.57 million, with net sales of 0.00 million and a net profit of -10.21 million over the latest four quarters. Shareholder's funds are 2.58 million, and total assets are 4.58 million as of Dec'24.